Company intelligence / Profile preview

AfaSci, Inc.

Burlingame, California, United Statesafasci.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

All current therapeutic candidates are at the preclinical stage. Two lead programs for neuropathic and neuroinflammatory pain are ready for IND-enabling studies. The company’s research has been validated by NIH grants and peer-reviewed publications. No active clinical trials are registered as of now.

Therapeutic areas: Neurology
Modalities: PeptidesSmall molecules
Industry: Biotech

Drug pipeline

5 assets

AFA-281

4 more assets in the full pipeline.

Request access →

Partnerships

Academic collaborations with Stanford University, Harvard University, UCLA, UC Davis, Kansas State University

Beyond the preview

Go deeper on AfaSci, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AfaSci, Inc..

Explore the full profile